김효송
#위암#육종#항암약물치료#신약치료
|
학력
1996.3-2002.2 국립경상대학교 의과대학
2002.3-2007.2 삼성서울병원 내과 전공의 (내과 전문의)
2008.3-2009.2 삼성서울병원 혈액종양학과 임상강사
2006.3-2008.2 성균관대학교 대학원 석사
2009.3-2013.8 성균관대학교 대학원 박사
2002.3-2007.2 삼성서울병원 내과 전공의 (내과 전문의)
2008.3-2009.2 삼성서울병원 혈액종양학과 임상강사
2006.3-2008.2 성균관대학교 대학원 석사
2009.3-2013.8 성균관대학교 대학원 박사
경력
2002.3-2003.2 삼성서울병원 인턴 (의사)
2004.3-2008.2 삼성서울병원 내과 전공의 (내과 전문의)
2008.3-2009.2 삼성서울병원 혈액종양학과 전임의
2009.3-2010.2 연세의대 내과학교실 임상연구 조교수
2010.3-2017.2 연세의대 내과학교실 임상조교수
2017.3-현재 연세의대 내과학교실 조교수
2004.3-2008.2 삼성서울병원 내과 전공의 (내과 전문의)
2008.3-2009.2 삼성서울병원 혈액종양학과 전임의
2009.3-2010.2 연세의대 내과학교실 임상연구 조교수
2010.3-2017.2 연세의대 내과학교실 임상조교수
2017.3-현재 연세의대 내과학교실 조교수
논문
1.Kim HS, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, Ahn JS, Kang WK, Park K, Im YH.. Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat. 2009 Mar 26
2.Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, Lim DH, Kim K, Kim SJ, Ko Y, Ki CS, Jo SJ, Lee JW, Kim WS. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2009 Mar 27:1-7
3.Kim HS, Yi SY, Jun HJ, Lee J, Park JO, Park YS, Jang J, Kim HJ, Ko Y, Lim HY, Kang WK. Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
Oncology. 2008 April 16, 73:192-7.
4.HS Kim, K Park, HJ Jun, SY Yi, J Lee, JS Ahn, YH Park, S Kim, Sl Lee, MJ Ahn
Comparison of survival between the pre- and post-gefitinib eras for advanced non-small cell lung cancer patients. Oncology. 2009 Feb 25;76(4):239-246
5.HS Kim, WS Kim, CW Jung, HY Choi, HM Lee, SS Jeon, H Ha. IG Hwang, S Lee, HY Lim. Molecular Biomarker for Advanced Renal Cell Carcinoma. Urologic Oncology. 2008 Oct 29 [Epub ahead of print]
6.Kim HS, Yi SY, Jun HJ, Ahn JS, Ahn MJ, Lee J, Kim Y, Cui ZY, Hong HJ, Kim JM, Li S, Hwang IG, Park K. L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. APMIS. 2009 Feb;117(2):140-6.
7.Hyo Song Kim, Youngwook Kim, Zheng Yun Cui, Hye-sook Lee,Jin Seok Ahn, Chan Keum Park, Keunchil Park and Myung-ju Ahn. Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung. ANTICANCER RESEARCH. 2009.Vol 29
8.Kim HS, Chang WI, Kim YC, Yi SY, Kil JS, Hahn JY, Kang M, Lee MS, Lee SH. Catecholamine cardiomyopathy associated with paraganglioma rescued by percutaneous cardiopulmonary support: inverted Takotsubo contractile pattern. Circ J. 2007 Dec;71(12):1993-5.
9.HS Kim, HJ Jun, HW Chang, HK Choi, SY Yi, GY Kwon, WS Kim. A case of leukemoid reaction in a patient with advanced transitional cell carcinoma. Korean Journal of Medicine 2006 , Vol 71,
10.Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K.. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008 Jul 8; 167-172
11.Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 2008 Oct 7;
12.Kim KH, Park YS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim DH, Ji SH, Park MJ, Lee J, Park SH, Park JO, Lim HY, Kang WK. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer.
Cancer Chemother Pharmacol. 2008 Dec 6
13.Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2008 Jun 62(1): 77-84
14.Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung Cancer Cancer Chemother Pharmacol. 2009 Feb 17.
15.Ji SH, Lim DH, Yi SY, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer. 2009 Apr 9;9(1):110
16.Yang JH, Park SW, Yang JH, Cho SW, Kim HS, Choi KA, Kim HJ. Dynamic left ventricular outflow tract obstruction without basal septal hypertrophy, caused by catecholamine therapy and volume depletion. Korean J Intern Med. 2008 Jun;23(2):106-9.
17.Chang
Catecholamine cardiomyopathy associated with paraganglioma rescued by percutaneous cardiopulmonary support - Inverted takotsubo contractile pattern
CIRCULATION JOURNAL 71/12 :1993-1995,2007
Clinical outcome of gastric cancer patients with bone marrow metastases
ONCOLOGY 73/3-4 :192-197,2007
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
Cancer Chemotherapy And Pharmacology 62/1 :77-84,2008
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
British Journal Of Cancer 99/1 :167-172,2008
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
Cancer Research And Treatment 41/2 :67-72,2009
Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy
Bmc Cancer 9/205 :-,2009
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 64/5 :917-924,2009
Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
Journal Of Thoracic Oncology 4/7 :809-815,2009
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
Bmc Cancer 9/110 :1-6,2009
L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors
Apmis 117/2 :140-146,2009
Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung
Anticancer Research 29/5 :1817-1822,2009
Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma
Leukemia & Lymphoma 50/5 :757-763,2009
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
Breast Cancer Research And Treatment 118/1 :89-97,2009
Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras
Oncology 76/4 :239-246,2009
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 63/6 :1141-1145,2009
The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
Annals of Surgical Oncology 17/12 :3259-3268,2010
Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
Cancer Research and Treatment 42/3 :180-184,2010
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer
Anti-Cancer Drugs 21/1 :107-112,2010
Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
Cancer Research and Treatment 42/4 :217-224,2010
Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study
Bmc Cancer 10/167 :-,2010
Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy
Apmis 118/ :941-948,2010
Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy
Urologic Oncology-Seminars And Original Investigations 28/2 :157-163,2010
A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis
ONCOLOGY 80/1-2 :142-150,2011
Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
ONCOLOGY 80/5-6 :395-405,2011
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 68/0 :991-999,2011
Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 41/ :1344-1350,2011
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer
EUROPEAN JOURNAL OF CANCER 48/ :518-526,2012
External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer
ANNALS OF ONCOLOGY 23/ :361-U336,2012
Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
Cancer Research and Treatment 44/1 :43-49,2012
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
CANCER CHEMOTHERAPY AND PHARMACOLOGY 70/4 :539-546,2012
Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 43/10 :996-1003,2013
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
SUPPORTIVE CARE IN CANCER 21/6 :1751-1759,2013
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/ :825-835,2013
Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/4 :853-860,2013
Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study
JOURNAL OF CLINICAL PATHOLOGY 67/1 :33-39,2014
Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study
ONCOLOGY 86/5-6 :329-335,2014
Ifosfamide-induced Fanconi syndrome with diabetes insipidus
KOREAN JOURNAL OF INTERNAL MEDICINE 29/2 :246-249,2014
Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
CANCER RESEARCH AND TREATMENT 46/2 :141-147,2014
PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
ONCOLOGY 88/2 :76-85,2015
Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer
ANNALS OF SURGICAL ONCOLOGY 22/1 :224-231,2015
Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
CANCER RESEARCH AND TREATMENT 47/1 :9-17,2015
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma
ONCOTARGET 6/4 :2562-2572,2015
The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer
LUNG CANCER 88/3 :325-331,2015
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: A retrospective case series
BMC CANCER 15/154 :1-7,2015
Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
ONCOLOGY 88/3 :147-156,2015
Leiomyosarcoma: investigation of prognostic factors for risk-stratification model
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 20/6 :1226-1232,2015
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
ONCOTARGET 6/42 :44971-44984,2015
골종양의 항암치료에 대한 전략
대한정형외과학회지 50/6 :438-443,2015
Multidisciplinary treatment of inferior vena cava leiomyosarcoma.
ANZ JOURNAL OF SURGERY 86/1-2 :104-105,2016
Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
ANNALS OF SURGERY 263/1 :96-102,2016
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites
ONCOTARGET 7/7 :8055-8066,2016
Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience.
JOURNAL OF CANCER 7/9 :1174-1180,2016
Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
ONCOTARGET 7/17 :24549-24558,2016
PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma
ONCOTARGET 7/21 :30691-30701,2016
Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
ANNALS OF NUCLEAR MEDICINE 30/4 :279-286,2016
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
BMC CANCER 16/434 :1-7,2016
Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: Implications for individualized therapy
ONCOTARGET 7/28 :44608-44620,2016
Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 46/6 :507-516,2016
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
CANCER RESEARCH AND TREATMENT 48/2 :553-560,2016
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
ONCOTARGET 7/9 :10,547-10,556,2016
Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.
CANCER RESEARCH AND TREATMENT 48/4 :1,286-1,292,2016
Recursive Partition Analysis of Peritoneal and Systemic Recurrence in Patients With Gastric Cancer Who Underwent D2 Gastrectomy: Implications for Neoadjuvant Therapy Consideration
JOURNAL OF SURGICAL ONCOLOGY 114/7 :859-864,2016
Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm
ONCOTARGET 7/44 :72,099-72,112,2016
A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE 2/5 :a000992-,2016
Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma
APMIS 125/3 :223-229,2017
Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
ONCOTARGET 8/19 :31,169-31,179,2017
Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma
CANCER MEDICINE 6/6 :1,311-1,322,2017
Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
ONCOTARGET 8/24 :38,389-38,398,2017
Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer
BRITISH JOURNAL OF SURGERY 104/7 :877-884,2017
Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1
CANCER RESEARCH AND TREATMENT 49/3 :717-726,2017
Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
ONCOTARGET 8/37 :61,837-61,845,2017
Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer
CLINICAL & TRANSLATIONAL ONCOLOGY 19/10 :1,268-1,275,2017
Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea
CANCER RESEARCH AND TREATMENT 50/1 :118-128,2018
Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
BMC CANCER 18/1 :158-165,2018
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.
KOREAN JOURNAL OF INTERNAL MEDICINE 33/2 :383-390,2018
The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status
GASTRIC CANCER 21/2 :213-224,2018
Prognostic significance of preoperative CT findings in patients with advanced gastric cancer who underwent curative gastrectomy
PLOS ONE 13/8 :e0202207-e0202220,2018
A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
AAPS JOURNAL 20/4 :72-87,2018
Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
ANNALS OF SURGICAL ONCOLOGY 25/11 :3,222-3,230,2018
Efficacy of Postoperative Radiotherapy Using Modern Techniques in Patients with Retroperitoneal Soft Tissue Sarcoma
YONSEI MEDICAL JOURNAL 59/9 :1,049-1,056,2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
CLINICAL CANCER RESEARCH 24/21 :5,272-5,281,2018
Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
BMC CANCER 18/1 :1116-1127,2018
S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
CANCER RESEARCH AND TREATMENT 51/1 :1-11,2019
Clinical analysis of patients with skeletal metastasis of lung cancer.
BMC CANCER 19/1 :303-303,2019
Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer
RADIOTHERAPY AND ONCOLOGY 140/ :143-149,2019
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
CANCER RESEARCH AND TREATMENT 51/2 :819-831,2019
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
ONCOLOGY 96/2 :59-69,2019
Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
CANCER RESEARCH AND TREATMENT 51/4 :1,380-1,391,2019
Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
Journal for ImmunoTherapy of Cancer 7/1 :e268-,2019
Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer
GASTRIC CANCER 22/6 :1,153-1,163,2019
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
EUROPEAN JOURNAL OF CANCER 112/ :20-28,2019
2.Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, Lim DH, Kim K, Kim SJ, Ko Y, Ki CS, Jo SJ, Lee JW, Kim WS. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2009 Mar 27:1-7
3.Kim HS, Yi SY, Jun HJ, Lee J, Park JO, Park YS, Jang J, Kim HJ, Ko Y, Lim HY, Kang WK. Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
Oncology. 2008 April 16, 73:192-7.
4.HS Kim, K Park, HJ Jun, SY Yi, J Lee, JS Ahn, YH Park, S Kim, Sl Lee, MJ Ahn
Comparison of survival between the pre- and post-gefitinib eras for advanced non-small cell lung cancer patients. Oncology. 2009 Feb 25;76(4):239-246
5.HS Kim, WS Kim, CW Jung, HY Choi, HM Lee, SS Jeon, H Ha. IG Hwang, S Lee, HY Lim. Molecular Biomarker for Advanced Renal Cell Carcinoma. Urologic Oncology. 2008 Oct 29 [Epub ahead of print]
6.Kim HS, Yi SY, Jun HJ, Ahn JS, Ahn MJ, Lee J, Kim Y, Cui ZY, Hong HJ, Kim JM, Li S, Hwang IG, Park K. L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. APMIS. 2009 Feb;117(2):140-6.
7.Hyo Song Kim, Youngwook Kim, Zheng Yun Cui, Hye-sook Lee,Jin Seok Ahn, Chan Keum Park, Keunchil Park and Myung-ju Ahn. Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung. ANTICANCER RESEARCH. 2009.Vol 29
8.Kim HS, Chang WI, Kim YC, Yi SY, Kil JS, Hahn JY, Kang M, Lee MS, Lee SH. Catecholamine cardiomyopathy associated with paraganglioma rescued by percutaneous cardiopulmonary support: inverted Takotsubo contractile pattern. Circ J. 2007 Dec;71(12):1993-5.
9.HS Kim, HJ Jun, HW Chang, HK Choi, SY Yi, GY Kwon, WS Kim. A case of leukemoid reaction in a patient with advanced transitional cell carcinoma. Korean Journal of Medicine 2006 , Vol 71,
10.Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K.. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008 Jul 8; 167-172
11.Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 2008 Oct 7;
12.Kim KH, Park YS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim DH, Ji SH, Park MJ, Lee J, Park SH, Park JO, Lim HY, Kang WK. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer.
Cancer Chemother Pharmacol. 2008 Dec 6
13.Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2008 Jun 62(1): 77-84
14.Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung Cancer Cancer Chemother Pharmacol. 2009 Feb 17.
15.Ji SH, Lim DH, Yi SY, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer. 2009 Apr 9;9(1):110
16.Yang JH, Park SW, Yang JH, Cho SW, Kim HS, Choi KA, Kim HJ. Dynamic left ventricular outflow tract obstruction without basal septal hypertrophy, caused by catecholamine therapy and volume depletion. Korean J Intern Med. 2008 Jun;23(2):106-9.
17.Chang
Catecholamine cardiomyopathy associated with paraganglioma rescued by percutaneous cardiopulmonary support - Inverted takotsubo contractile pattern
CIRCULATION JOURNAL 71/12 :1993-1995,2007
Clinical outcome of gastric cancer patients with bone marrow metastases
ONCOLOGY 73/3-4 :192-197,2007
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
Cancer Chemotherapy And Pharmacology 62/1 :77-84,2008
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
British Journal Of Cancer 99/1 :167-172,2008
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
Cancer Research And Treatment 41/2 :67-72,2009
Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy
Bmc Cancer 9/205 :-,2009
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 64/5 :917-924,2009
Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
Journal Of Thoracic Oncology 4/7 :809-815,2009
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
Bmc Cancer 9/110 :1-6,2009
L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors
Apmis 117/2 :140-146,2009
Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung
Anticancer Research 29/5 :1817-1822,2009
Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma
Leukemia & Lymphoma 50/5 :757-763,2009
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
Breast Cancer Research And Treatment 118/1 :89-97,2009
Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras
Oncology 76/4 :239-246,2009
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 63/6 :1141-1145,2009
The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
Annals of Surgical Oncology 17/12 :3259-3268,2010
Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
Cancer Research and Treatment 42/3 :180-184,2010
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer
Anti-Cancer Drugs 21/1 :107-112,2010
Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
Cancer Research and Treatment 42/4 :217-224,2010
Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study
Bmc Cancer 10/167 :-,2010
Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy
Apmis 118/ :941-948,2010
Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy
Urologic Oncology-Seminars And Original Investigations 28/2 :157-163,2010
A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis
ONCOLOGY 80/1-2 :142-150,2011
Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
ONCOLOGY 80/5-6 :395-405,2011
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 68/0 :991-999,2011
Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 41/ :1344-1350,2011
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer
EUROPEAN JOURNAL OF CANCER 48/ :518-526,2012
External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer
ANNALS OF ONCOLOGY 23/ :361-U336,2012
Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
Cancer Research and Treatment 44/1 :43-49,2012
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
CANCER CHEMOTHERAPY AND PHARMACOLOGY 70/4 :539-546,2012
Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 43/10 :996-1003,2013
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
SUPPORTIVE CARE IN CANCER 21/6 :1751-1759,2013
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/ :825-835,2013
Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/4 :853-860,2013
Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study
JOURNAL OF CLINICAL PATHOLOGY 67/1 :33-39,2014
Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study
ONCOLOGY 86/5-6 :329-335,2014
Ifosfamide-induced Fanconi syndrome with diabetes insipidus
KOREAN JOURNAL OF INTERNAL MEDICINE 29/2 :246-249,2014
Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
CANCER RESEARCH AND TREATMENT 46/2 :141-147,2014
PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
ONCOLOGY 88/2 :76-85,2015
Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer
ANNALS OF SURGICAL ONCOLOGY 22/1 :224-231,2015
Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
CANCER RESEARCH AND TREATMENT 47/1 :9-17,2015
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma
ONCOTARGET 6/4 :2562-2572,2015
The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer
LUNG CANCER 88/3 :325-331,2015
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: A retrospective case series
BMC CANCER 15/154 :1-7,2015
Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
ONCOLOGY 88/3 :147-156,2015
Leiomyosarcoma: investigation of prognostic factors for risk-stratification model
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 20/6 :1226-1232,2015
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
ONCOTARGET 6/42 :44971-44984,2015
골종양의 항암치료에 대한 전략
대한정형외과학회지 50/6 :438-443,2015
Multidisciplinary treatment of inferior vena cava leiomyosarcoma.
ANZ JOURNAL OF SURGERY 86/1-2 :104-105,2016
Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
ANNALS OF SURGERY 263/1 :96-102,2016
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites
ONCOTARGET 7/7 :8055-8066,2016
Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience.
JOURNAL OF CANCER 7/9 :1174-1180,2016
Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
ONCOTARGET 7/17 :24549-24558,2016
PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma
ONCOTARGET 7/21 :30691-30701,2016
Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
ANNALS OF NUCLEAR MEDICINE 30/4 :279-286,2016
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
BMC CANCER 16/434 :1-7,2016
Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: Implications for individualized therapy
ONCOTARGET 7/28 :44608-44620,2016
Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 46/6 :507-516,2016
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
CANCER RESEARCH AND TREATMENT 48/2 :553-560,2016
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
ONCOTARGET 7/9 :10,547-10,556,2016
Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.
CANCER RESEARCH AND TREATMENT 48/4 :1,286-1,292,2016
Recursive Partition Analysis of Peritoneal and Systemic Recurrence in Patients With Gastric Cancer Who Underwent D2 Gastrectomy: Implications for Neoadjuvant Therapy Consideration
JOURNAL OF SURGICAL ONCOLOGY 114/7 :859-864,2016
Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm
ONCOTARGET 7/44 :72,099-72,112,2016
A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE 2/5 :a000992-,2016
Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma
APMIS 125/3 :223-229,2017
Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
ONCOTARGET 8/19 :31,169-31,179,2017
Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma
CANCER MEDICINE 6/6 :1,311-1,322,2017
Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
ONCOTARGET 8/24 :38,389-38,398,2017
Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer
BRITISH JOURNAL OF SURGERY 104/7 :877-884,2017
Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1
CANCER RESEARCH AND TREATMENT 49/3 :717-726,2017
Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
ONCOTARGET 8/37 :61,837-61,845,2017
Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer
CLINICAL & TRANSLATIONAL ONCOLOGY 19/10 :1,268-1,275,2017
Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea
CANCER RESEARCH AND TREATMENT 50/1 :118-128,2018
Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
BMC CANCER 18/1 :158-165,2018
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.
KOREAN JOURNAL OF INTERNAL MEDICINE 33/2 :383-390,2018
The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status
GASTRIC CANCER 21/2 :213-224,2018
Prognostic significance of preoperative CT findings in patients with advanced gastric cancer who underwent curative gastrectomy
PLOS ONE 13/8 :e0202207-e0202220,2018
A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
AAPS JOURNAL 20/4 :72-87,2018
Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
ANNALS OF SURGICAL ONCOLOGY 25/11 :3,222-3,230,2018
Efficacy of Postoperative Radiotherapy Using Modern Techniques in Patients with Retroperitoneal Soft Tissue Sarcoma
YONSEI MEDICAL JOURNAL 59/9 :1,049-1,056,2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
CLINICAL CANCER RESEARCH 24/21 :5,272-5,281,2018
Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
BMC CANCER 18/1 :1116-1127,2018
S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
CANCER RESEARCH AND TREATMENT 51/1 :1-11,2019
Clinical analysis of patients with skeletal metastasis of lung cancer.
BMC CANCER 19/1 :303-303,2019
Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer
RADIOTHERAPY AND ONCOLOGY 140/ :143-149,2019
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
CANCER RESEARCH AND TREATMENT 51/2 :819-831,2019
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
ONCOLOGY 96/2 :59-69,2019
Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
CANCER RESEARCH AND TREATMENT 51/4 :1,380-1,391,2019
Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
Journal for ImmunoTherapy of Cancer 7/1 :e268-,2019
Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer
GASTRIC CANCER 22/6 :1,153-1,163,2019
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
EUROPEAN JOURNAL OF CANCER 112/ :20-28,2019
저서
저서 내용이 없습니다.
보도자료
[SBS] 고통 이겨낸 긍정의 힘…말기암 환자의 놀라운 변화 - 종양내과 ...
http://news.sbs.co.kr/news/endPage.do?news_id=N1004137282&plink=SEARCH&cooper=SBSNEWSSEARCH&plink=COPYPASTE&cooper=SBSNEWSEND
[CTS 기독교 TV, 예수사랑 여기에] 항암치료 환자 설명 인터뷰 - 종...
http://www.cts.tv/prog/program/loveofj/list.asp?PID=P44
[KBS 생로병사의 비밀] 혈관을 겨누는 화살, 짠맛 중독! - 심장내과 ...
http://www.kbs.co.kr/1tv/sisa/health/view/vod/index.html
http://news.sbs.co.kr/news/endPage.do?news_id=N1004137282&plink=SEARCH&cooper=SBSNEWSSEARCH&plink=COPYPASTE&cooper=SBSNEWSEND
[CTS 기독교 TV, 예수사랑 여기에] 항암치료 환자 설명 인터뷰 - 종...
http://www.cts.tv/prog/program/loveofj/list.asp?PID=P44
[KBS 생로병사의 비밀] 혈관을 겨누는 화살, 짠맛 중독! - 심장내과 ...
http://www.kbs.co.kr/1tv/sisa/health/view/vod/index.html
포스팅
포스팅 내용이 없습니다.
영상자료
영상자료 내용이 없습니다.
발표자료
발표자료 내용이 없습니다.